BTS
KRYS icon

BB&T Securities’s Krystal Biotech KRYS Stock Holding History

BB&T Securities’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$382K Hold
11,000
– – ﹤0.01% 1214
2019
Q2 		$442K Hold
11,000
– – ﹤0.01% 1150
2019
Q1 		$361K Hold
11,000
– – ﹤0.01% 1212
2018
Q4 		$228K Buy
+11,000
New +$230K ﹤0.01% 1309

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB&T Securities's KRYS Position: Q3 2019 in Review

BB&T Securities held its Krystal Biotech (KRYS) position steady in Q3 2019 at 11,000 shares worth $382K. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

BB&T Securities first reported a position in KRYS in Q4 2018 and has held it in 4 quarters since. The position peaked at $442K in Q2 2019. 85 funds tracked by Wall St. Rank hold KRYS as of Q3 2019.

  • BB&T Securities held 11,000 shares of Krystal Biotech worth $382K as of Q3 2019.
  • BB&T Securities left its Krystal Biotech share count unchanged in Q3 2019.
  • Krystal Biotech made up ﹤0.01% of BB&T Securities's portfolio in Q3 2019, its #1214 holding.
  • BB&T Securities first reported a position in Krystal Biotech in Q4 2018 and has held it in 4 quarters since.
  • BB&T Securities's Krystal Biotech position peaked at $442K in Q2 2019.
  • 85 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.